North China Pharmaceutical: Obtained the registration certificate for Raltegravir injection.

On April 20, Huabei Pharmaceutical announced that the company recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the Injection of Letermovir. This drug is used to prevent adult cytomegalovirus infection and disease in patients receiving allogeneic hematopoietic stem cell transplantation, and is considered to have passed the evaluation of generic drug quality and efficacy consistency. As of now, a total of 14.79 million yuan has been invested in the research and development of this product. There are a total of 5 companies in China holding the registration certificate for this drug, with estimated domestic market sales of 23.6 million yuan in 2024 and 33.84 million yuan in 2025. This certification is a further supplement to the company's formulated products, which is beneficial for improving the product structure in the field of anti-infection and immunosuppressants. However, sales of formulated products are susceptible to policy and market environment influences, thus there is uncertainty.